Is Intra-Articular Injection of Synvisc Associated with a Delay to Knee Arthroplasty in Patients with Knee Osteoarthritis?


Journal

Cartilage
ISSN: 1947-6043
Titre abrégé: Cartilage
Pays: United States
ID NLM: 101518378

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 22 5 2018
medline: 19 5 2020
entrez: 22 5 2018
Statut: ppublish

Résumé

There is debate about the effectiveness of intra-articular (IA) hyaluronic acid (HA) injections. We asked the following questions: (1) What is the epidemiology of IA HA use in knee arthroplasty (KA) patients? (2) Is Synvisc associated with a delay to KA? (3) Is there a difference in the delay to KA with the number of HA courses? The Optum Clinformatics data set (2006-June 2016) was used to identify patients with knee osteoarthritis (OA). Patients who did not receive IA HA were identified, along with those who received Synvisc or non-Synvisc HA. The median duration from knee OA to KA was compared using quantile regression modeling with propensity score weighting. The trend in time to KA with each HA course was evaluated. Of 4,027,848 knee OA patients, 141,305 patients underwent KA. Overall median time from knee OA diagnosis to KA was 1.2 years (average: 1.9 ± 1.9 years; interquartile range of 0.4-2.8 years). HA patients had significantly longer adjusted median time to KA by at least 7 months ( Most KA patients did not use HA (73.7%) and when received, it was associated with a longer median time to KA by at least 7 months, though the cause and effect could not be examined. The delay to KA increased with more HA courses.

Identifiants

pubmed: 29779404
doi: 10.1177/1947603518775792
pmc: PMC6755870
doi:

Substances chimiques

Biocompatible Materials 0
Viscosupplements 0
hylan 125935-84-4
Hyaluronic Acid 9004-61-9

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

423-431

Références

Osteoarthritis Cartilage. 2014 Mar;22(3):363-88
pubmed: 24462672
Arthritis Care Res (Hoboken). 2012 Jun;64(6):853-61
pubmed: 22262497
Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S28-33
pubmed: 26806183
Am J Public Health. 1994 Mar;84(3):351-8
pubmed: 8129049
BMC Musculoskelet Disord. 2011 Apr 28;12:83
pubmed: 21527024
Ann Intern Med. 2015 Jan 6;162(1):46-54
pubmed: 25560713
J Manag Care Pharm. 2007 Mar;13(2):113-121
pubmed: 17330972
Arthritis Care Res (Hoboken). 2012 Apr;64(4):465-74
pubmed: 22563589
Ann Rheum Dis. 2012 Sep;71(9):1454-60
pubmed: 22294639
Int Orthop. 2011 Dec;35(12):1783-9
pubmed: 21404023
Med Care. 2010 Sep;48(9):785-91
pubmed: 20706165
Blood Coagul Fibrinolysis. 2012 Oct;23(7):580-3
pubmed: 22885769
BMC Musculoskelet Disord. 2015 Oct 26;16:321
pubmed: 26503103
Pain Med. 2012 Jun;13(6):740-53
pubmed: 22621287
PLoS One. 2015 Dec 22;10(12):e0145776
pubmed: 26694145
Ann Rheum Dis. 2011 Nov;70(11):1957-62
pubmed: 21852252
Semin Arthritis Rheum. 2015 Oct;45(2):132-9
pubmed: 26142320
BioDrugs. 2012 Aug 1;26(4):257-68
pubmed: 22734561
Clin Exp Rheumatol. 2004 Nov-Dec;22(6):699-706
pubmed: 15638043
Ann Rheum Dis. 2003 Dec;62(12):1145-55
pubmed: 14644851
J Am Acad Orthop Surg. 2013 Sep;21(9):571-6
pubmed: 23996988
Cartilage. 2016 Oct;7(4):322-32
pubmed: 27688841
J Bone Joint Surg Am. 2014 Apr 16;96(8):624-30
pubmed: 24740658
Clin Orthop Relat Res. 2015 Aug;473(8):2722-6
pubmed: 25773902
J Arthroplasty. 2016 Aug;31(8):1667-73
pubmed: 26895820
Clin Orthop Relat Res. 2014 Jul;472(7):2028-34
pubmed: 24218162
Ann R Coll Surg Engl. 2013 Nov;95(8):545-51
pubmed: 24165334
Am J Sports Med. 2016 Aug;44(8):2158-65
pubmed: 26578719
Arthritis Res Ther. 2014 Jan 21;16(1):R18
pubmed: 24443804
J Med Assoc Thai. 2009 Dec;92 Suppl 6:S63-8
pubmed: 20120667

Auteurs

Kevin L Ong (KL)

Exponent, Inc., Philadelphia, PA, USA.

Maria Runa (M)

Exponent, Inc., Philadelphia, PA, USA.

Edmund Lau (E)

Exponent, Inc., Menlo Park, CA, USA.

Roy Altman (R)

Academic Speakers of America, Agua Dulce, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH